Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;108(6):1680-1684.
doi: 10.3324/haematol.2022.282264.

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Joshua N Gustine  1 , Raphael E Szalat  1 , Andrew Staron  1 , Tracy Joshi  1 , Lisa Mendelson  1 , J Mark Sloan  1 , Vaishali Sanchorawala  2
Affiliations

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Joshua N Gustine et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival in patients with AL amyloidosis associated with Waldenström macroglobulinemia. (A, B) Kaplan-Meier curves for event-free survival (A) and overall survival (B) for the entire cohort. (C, D) Kaplan-Meier curves for event-free survival (C) and overall survival (D) stratified by depth of free light chain response. (E, F) Kaplan-Meier curves for event-free survival (E) and overall survival (F) stratified by depth of IgM response. WM-AL: Waldenström macroglobulinemia associated with AL amyloidosis; NR: no response; PR: partial response; VGPR: very good partial response; CR: complete response; MR: minor response.
See this image and copyright information in PMC

References

    1. Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020;34(5):1373-1382. - PMC - PubMed
    1. Sissoko M, Sanchorawala V, Seldin D, et al. Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid. 2015;22(4):229-235. - PubMed
    1. Zanwar S, Abeykoon JP, Ansell SM, et al. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia. 2019;33(3):790-794. - PubMed
    1. Manwani R, Sachchithanantham S, Mahmood S, et al. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood. 2018;132(7):761-764. - PubMed
    1. Milani P, Schönland S, Merlini G, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018;132(18):1988-1991. - PubMed

MeSH terms

Substances